# ARS Pharmaceuticals (SPRY) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SPRY
## Company Profile
- Ticker: SPRY
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 6.05 USD
- Market cap: 883799031.8000001 USD
- Last updated: 2026-08-12
## Business Overview
### Needle-Free Epinephrine Company
ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. Neffy is an approved needle-free emergency epinephrine treatment in the United States and European Union.
### Neffy Commercialization
The company is building U.S. sales, payer access, prescription-refill programs, and pharmacy affordability support while expanding internationally through regional partners. Health Canada has approved neffy, with ALK responsible for Canadian commercialization.
### Patient-Centered Delivery Strategy
The nasal formulation is intended to remove barriers associated with injectable epinephrine, including needle anxiety, complex administration, and hesitation during emergencies. ARS is building its commercial strategy around portability, ease of use, and broader willingness to carry treatment.
### Intranasal Epinephrine Platform Expansion
Beyond emergency allergy treatment, ARS is evaluating intranasal epinephrine for acute flares of chronic spontaneous urticaria and has advanced the program into a Phase 2b study.
### International Partnership Model
ARS uses regional partners to extend neffy beyond its direct U.S. commercial organization. These partners assume responsibility for local regulatory, distribution, and launch activities while broadening the geographic value of the product.
## Why The Stock Is Moving

The latest monitored company update is “ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Interim Phase 2b data for intranasal epinephrine in chronic spontaneous urticaria in the first quarter of 2027.

## Recent News
- 2026-08-13 20:01 EST — [ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-outlines-strategic-priorities-including-a-focused-commercial-788a83c6) — Source: ARS Pharmaceuticals
- 2026-08-03 11:30 EST — [ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-announces-conference-call-and-webcast-on-august-13-outlining-0390283c) — Source: ARS Pharmaceuticals
- 2026-07-07 20:30 EST — [ARS Pharmaceuticals Announces CEO Succession](https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-announces-ceo-succession-533f8792) — Source: ARS Pharmaceuticals
- 2026-06-24 20:05 EST — [ARS Pharmaceuticals Provides Commercial and Financial Updates](https://biopharmsignal.com/news/SPRY/ars-pharmaceuticals-provides-commercial-and-financial-updates-8c04d85d) — Source: ARS Pharmaceuticals
- 2026-06-04 12:00 EST — [Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies](https://biopharmsignal.com/news/SPRY/drew-brees-collaborates-with-ars-pharmaceuticals-to-raise-awareness-about-living-61e393ec) — Source: ARS Pharmaceuticals